Sponsors (2)
The bill improves detection, education, and access to treatment for tardive dyskinesia—potentially reducing harm for people on antipsychotics—at the cost of higher short‑term program and treatment expenses and a risk of increased stigma or unintended impacts on antipsychotic use.
People taking antipsychotic medications will be more likely to receive routine screening for tardive dyskinesia (TD), enabling earlier detection and treatment to reduce undiagnosed cases and related harm.
Clinicians, patients, and care partners will get increased education and awareness about TD, improving recognition of symptoms and aligning care with clinical guidance.
Patients diagnosed with TD could gain access to FDA‑approved treatments for symptom management, potentially improving quality of life for those affected.
Increased screening and education efforts will require additional clinician time and program resources, raising short‑term healthcare costs for providers, payers, or taxpayers.
More screening is likely to produce more TD diagnoses that require ongoing treatment, which could increase out‑of‑pocket costs for some patients if insurance coverage is incomplete.
A strong emphasis on screening could inadvertently stigmatize people treated with antipsychotics or discourage necessary antipsychotic use if screening is not balanced with careful clinical context.
Based on analysis of 2 sections of legislative text.
Encourages education, awareness, and routine screening for tardive dyskinesia among people treated with antipsychotics so care follows clinical best practices.
Official title: Designating the first full week in May as "Tardive Dyskinesia Awareness Week".
Introduced October 30, 2025 by Markwayne Mullin · Last progress October 30, 2025
Encourages increased education, awareness, and routine screening for tardive dyskinesia (TD) among people treated with antipsychotic medications so that care aligns with clinical best practices. The resolution notes rising antipsychotic prescribing, identifies groups at higher risk for TD, cites professional guidance recommending routine TD screening, and highlights FDA‑approved treatments.